GILD

NASDAQ Healthcare

Gilead Sciences, Inc. - Common Stock

Drug Manufacturers - General

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

๐Ÿ“Š Market Data
Price$131.65
Volume5,516,823
Market Cap163.40B
Dividend Yield %2.51%
Beta0.400
RSI (14-Day)31.9
200-Day MA$125.65
50-Day MA$140.08
52-Week High$157.29
52-Week Low$95.30
P/E Ratio19.42
Forward P/E13.69
Price / Book7.20
๐ŸŽฏ Investment Strategy Scores

GILD scores across each investment strategy. Higher is better for that strategy's goals.

๐Ÿ’ฐ Dividend Daddy 75/100โ–ฒ +1
High dividend yield + low volatility
๐Ÿš€ Moon Shot 48/100โ–ผ -4
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 77/100โ–ผ -5
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 7/100โ–ฒ +4
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿ‹ Institutional Whale (97/100) โ€” this strategy Large-cap, institutional-quality stocks.

Lowest fit among scored strategies: ๐ŸŽˆ Over-Hyped (7/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find GILD in your text

Paste any article, transcript, or post โ€” the tool will extract GILD and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.